Organon & Co.
Organon & Co. (NYSE: OGN) is a global healthcare company with a portfolio of more than 70 products focused on women’s health and general medicines, including biosimilars. Its women’s health products include contraceptives such as Nexplanon and NuvaRing, and fertility treatments such as Follistim AQ. General medicines… From the company’s description.
Over the twelve months to Sep 30, 2026, Organon & Co. reported revenue of $6.10B, down 3.2% from a year earlier, and net income of $213.00M. Its operating margin was 13.6%, and operations generated $843.00M in cash. In fiscal 2025, it reported revenue of $6.22B, down 2.9% from fiscal 2024, and net income of $187.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Organon & Co. does
In the company’s own words
Organon & Co. (NYSE: OGN) is a global healthcare company with a portfolio of more than 70 products focused on women’s health and general medicines, including biosimilars. Its women’s health products include contraceptives such as Nexplanon and NuvaRing, and fertility treatments such as Follistim AQ. General medicines include biosimilars for immunology and oncology, alongside established brands in cardiovascular, respiratory, dermatology, bone health and non-opioid pain management, including Zetia, Singulair and Vtama. The company sells prescription medicines and other products to wholesalers, retailers, hospitals, clinics, pharmacies, government agencies and managed healthcare providers. Organon reports three product groups: Women’s Health, Biosimilars and Established Brands, which generated approximately 28%, 11% and 59% of 2025 revenue, respectively. Revenue totaled $6.2 billion in 2025, with products distributed in more than 140 countries and territories. Organon operates six manufacturing facilities and had more than 10,000 employees worldwide at year-end 2025. Its website is www.organon.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- JERSEY CITY, NJ
- Fiscal year end
- December
- CIK
- 1821825
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Organon & Co. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Organon & Co.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Organon & Co.’s bonds, as funds hold them
Funds report holding 7 issues of Organon & Co.’s debt, $808.50M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.98%, maturing 2028 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Organon & Co. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Organon & Co.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Organon & Co.'s last four quarterly filings that the numbers alone won't show?”